 |
|
|
| |
Concentration-QT Analysis of Firsocostat,
a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Chia-Hsiang Hsueh, Mun Sang Yue, Victoria Millward, Darren Huber, Chuhan Chung, Robert P. Myers, Elijah Weber, Cara Nelson - Gilead Sciences, Inc., Foster City, California, USA
References: 1. Lawitz EJ, et al. Clin Gastroenterol Hepatol 2018;16:1983-91; 2. Loomba R, et al. Gastroenterology 2018;155:1463-73; 3. US Food & Drug Administration. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Oct 2012; 4. Westlin WF, et al. EASL 2016, oral FRI-355; 5. Garnett C, et al. J Pharmacokinet Pharmacodyn 2018;45:383-97.
Acknowledgments: We extend our thanks to the subjects for their participation in this study. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
